不同方法治疗早期声门型喉癌的疗效对比分析  

A comparative analysis on the curative effects of different treatment for early glottic laryngeal carcinoma patients

作　　者：代红磊 潘松林 马文学 官兵 刘涛 张正艳 DAI Honglei;PAN Songlin;MA Wenxue;GUAN Bing;LIU Tao;ZHANG Zhengyan(Department of Otolaryngology,Jingmen People’s Hospital,Jingchu Institute of Technology Affiliated Central Hospital,Jingmen 448000,China)

机构地区：[1]荆门市人民医院荆楚理工学院附属中心医院耳鼻咽喉科,湖北荆门448000

出　　处：《中国耳鼻咽喉颅底外科杂志》2024年第6期95-99,共5页Chinese Journal of Otorhinolaryngology-skull Base Surgery

基　　金：2021年荆门市科技局重点项目(2021YFZD016)。

摘　　要：目的研究早期声门型喉癌患者行不同方法治疗的效果。方法选取60例早期声门型喉癌患者,根据治疗方法不同分为3组,其中A组(支撑喉镜下CO_(2)激光术,n=20)、B组(低温等离子射频消融术,n=20)、C组(喉切除术,n=20),对3组患者进行疗效比较。结果3组患者并发症、复发率经比较差异无统计学意义(P>0.05)。与A、C组比较,B组手术时间更短,术中出血量更少,视觉模拟评分(VAS)、黏膜恢复评分更低,首次经口进食时间、首次发声时间及住院天数更短,喉功能改善率更高,经比较差异均具有统计学意义(P均<0.05)。结论早期声门型喉癌患者行低温等离子射频消融术及CO_(2)激光术可改善喉部功能、减轻疼痛,促进创面黏膜恢复、缩短疗程,值得临床推广应用。Objective To study the effect of different treatment for early glottic laryngeal carcinoma.Methods Sixty patients with early glottic laryngeal carcinoma were divided into group A(CO_(2) laser with support laryngoscope,n=20)and group B(low-temperature plasma radiofrequency ablation,n=20)and group C(laryngectomy,n=20).the curative effect of the three groups was compared.Results There was no significant difference in the complication and recurrence rate among the three groups(P>0.05),compared with group A and group C,group B had shorter operation time,less intraoperative blood loss,lower visual analogue scale(VAS)and mucosal recovery scores.First oral eating,first vocalization and hospital stay were shorter;the improvement rate of laryngeal function was higher,and the differences were statistically significant(all P<0.05).Conclusion Low-temperature plasma radiofrequency ablation and CO_(2) laser in patients with early glottic laryngeal carcinoma can improve laryngeal function,relieve pain,promote the recovery of wound mucosa,and shorten the course of treatment,which is worthy of clinical application.

关 键 词：早期声门型喉癌 CO 2激光术 低温等离子射频 喉切除 疗效 

分 类 号：R739.65[医药卫生—肿瘤]